Cryoskin™ is an active treatment for burns and hard to heal wounds, using viable donor cells to provide support for the healing process in the wound bed. It is only provided directly to medical professionals and treatment centres on a named-patient basis.

Cryoskin™ consists of a frozen mono-layer of undifferentiated allogenic keratinocytes attached, using specialist coating techniques, to a medical grade silicone backing, perforated to allow movement of exudate. The cell layer produces a ‘cocktail’ of growth factors and cytokines, which along with cell to cell interactions, encourage and promote the growth of the patient’s own cells to grow back at an increased rate.

The Cryoskin™ cells are from a fully screened donor that has been specially selected for their ability to grow at a desirable and expected rate, and grow in serum and animal free media; reducing any chance of an adverse patient reaction. They have been used to treat over 600 patients and are cultured to high levels of quality and reliability in GMP accredited cleanrooms.

The sheets are stored at -80C for up to 6 months and are individually sealed in sterile packages designed to be taken straight to theatre. Although manufactured under a Manufacturer’s Specials License from the Medicines and Healthcare Products Regulatory Agency (MHRA), no license is required to store the product at an end-user site, allowing local storage within hospitals for immediate use.

Cryoskin™ can been applied for a number of different treatments, including directly to the wounds site or as an adjunct to meshed grafting, where there has been noticed a significantly increase in rate at which meshes close and also a greatly reduced mesh scarring. IT has also been used over donor sites to allow for re-cropping on the same site more frequently.